Five questions before an oncology protocol is finalized

A protocol can be scientifically ambitious and still leave the development decision unclear. The questions below are a way to test a draft before individual choices harden into commitments across sites, data collection and medical review.

1. What decision should the study inform?

Start with the decision, not the schedule of assessments. Is the study meant to characterize early activity, justify a randomized trial or support a registrational filing? Write the decision in one sentence, then list which results would resolve it and which would leave it open. If a plausible result would not change what you do next, the objective needs another look.

2. Does the population match the question?

Read the disease setting, prior therapy, biomarker requirements and eligibility criteria together. A narrow population can make a signal easier to interpret and harder to enroll; a broad one can do the reverse. Check each criterion for a reason, and ask which ones sites will struggle to apply consistently.

3. Do the endpoints fit the evidence you need?

For each important endpoint, state what it measures, how and when it will be assessed, and what its interpretation depends on. FDA’s guidance on endpoints for cancer drug approval is a useful reference for the regulatory side, but it does not replace a program-specific discussion of what a result would mean.

4. Will the collected data support medical interpretation?

Walk a single patient through the protocol and the CRF as a reviewer would, from first dose through dose reduction, response assessment and discontinuation. Where does the story break? Missing dates, unlinked events and ambiguous response fields are far easier to fix before the first patient is enrolled.

5. Are the execution and dose assumptions explicit?

List what the design assumes about site capability, patient access, assessment burden and data availability. In early development, the dose-selection logic deserves its own discussion: FDA’s Project Optimus encourages consideration of efficacy, safety and tolerability, not only the maximum tolerated dose, when choosing an oncology dose.